Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Black Diamond Therapeutics Inc
(NQ:
BDTX
)
5.220
+0.240 (+4.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Black Diamond Therapeutics Inc
< Previous
1
2
Next >
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 08, 2024
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Changes to Board of Directors
April 11, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
April 07, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
April 03, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
March 05, 2024
Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutations
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
January 04, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
December 13, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 07, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 06, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
October 14, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces CEO Transition
September 18, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
September 11, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 11, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
June 29, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
June 28, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM
June 27, 2023
Black Diamond Therapeutics has announced encouraging initial data from a Phase 1 study of BDTX-1535, an investigational fourth-generation EGFR MasterKey
Via
Spotlight Growth
Black Diamond Therapeutics Inc. (NASDAQ: BDTX) Leading the Way in Tuesday Trading Based on Percentage Gain
June 27, 2023
Via
Investor Brand Network
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
June 27, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
June 13, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.